Action Global Blood Therapeutics - 0IVZ

Global Blood Therapeutics Inc (0IVZ) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

( - )

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients...

New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease

New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease...

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell...

European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and...

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to...

GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12...

GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen

GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0IVZ - Frequently Asked Questions (FAQ)

What is the current Global Blood Therapeutics Inc share price?

The current share price of Global Blood Therapeutics Inc is US$ 0,00

What is the 1 year trading range for Global Blood Therapeutics Inc share price?

Global Blood Therapeutics Inc has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Global Blood Therapeutics Inc (0IVZ)

Global Blood Therapeutics Inc (0IVZ) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

0IVZ Dernières nouvelles

MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease

GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen

0IVZ - Frequently Asked Questions (FAQ)

0IVZ Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Global Blood Therapeutics Inc (0IVZ)

Global Blood Therapeutics Inc (0IVZ) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

0IVZ Dernières nouvelles

MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease

GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen

0IVZ - Frequently Asked Questions (FAQ)

0IVZ Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE